NCT06984094 - First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults | Biotech Hunter

Enrollment

192

Participants

Timeline

Start Date

June 18, 2025

Primary Completion Date

March 3, 2026

Study Completion Date

June 30, 2026

Conditions

Respiratory Syncytial Virus VaccinationHuman Metapneumovirus VaccinationParainfluenza Vaccination

Interventions

BIOLOGICAL

SCB-1019T

SCB-1019T (bivalent recombinant RSV vaccine candidate) consists of two recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)) and RSV B strain (SCB-1019T(B)).

BIOLOGICAL

SCB-1022

SCB-1022 (combination recombinant RSV-hMPV vaccine candidate) consists of three recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)), RSV B strain (SCB-1019T(B)), and hMPV (SCB-1021).

BIOLOGICAL

SCB-1033

SCB-1033 (combination recombinant RSV-hMPV-PIV3 vaccine candidate) consists of four recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)), RSV B strain (SCB-1019T(B)), hMPV (SCB-1021) and PIV3 (SCB-1020).

Trial Locations (1)

5067

RECRUITING

Fusion Clinical Research, Adelaide